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The diversity of viral strategies to modulate complement activation indicates that this component of the
immune system has significant antiviral potential. One example is the Kaposi’s sarcoma-associated herpes-
virus (KSHV) complement control protein (KCP), which inhibits progression of the complement cascade.
Rhesus rhadinovirus (RRV), like KSHV, is a member of the subfamily Gammaherpesvirinae and currently
provides the only in vivo model of KSHV pathobiology in primates. In the present study, we characterized the
KCP homologue encoded by RRV, RRV complement control protein (RCP). Two strains of RRV have been
sequenced to date (H26-95 and 17577), and the RCPs they encode differ substantially in structure: RCP from
strain H26-95 has four complement control protein (CCP) domains, whereas RCP from strain 17577 has eight
CCP domains. Transcriptional analyses of the RCP gene (ORF4, referred to herein as RCP) in infected rhesus
macaque fibroblasts mapped the ends of the transcripts of both strains. They revealed that H26-95 encodes a
full-length, unspliced RCP transcript, while 17577 RCP generates a full-length unspliced mRNA and two
alternatively spliced transcripts. Western blotting confirmed that infected cells express RCP, and immune
electron microscopy disclosed this protein on the surface of RRV virions. Functional studies of RCP encoded
by both RRV strains revealed their ability to suppress complement activation by the classical (antibody-
mediated) pathway. These data provide the foundation for studies into the biological significance of gamma-
herpesvirus complement regulatory proteins in a tractable, non-human primate model.
The complement system bridges the innate and adaptive
components of the immune system and provides a rapid re-
sponse to infecting agents, including viruses. Complement ac-
tivation is directly lytic, by formation of the membrane attack
complex, and results in a number of other functional conse-
quences, including priming and recruiting the adaptive im-
mune system, e.g., through opsonization of foreign surfaces by
C3b and release of the anaphylatoxins C3a and C5a. As a
consequence, many viruses have evolved means to modulate
complement activation. The phylogenetic diversity of these
viruses and the different mechanisms by which they regulate
complement activation indicate that this immunomodulatory
activity has been acquired independently and at different times
(reviewed in reference 10).
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the eti-
ologic agent of Kaposi’s sarcoma (13), primary effusion lym-
phoma (12), and perhaps multicentric Castleman’s disease
(38). It encodes a multitude of proteins with demonstrated or
putative immunomodulatory activity (for review, see reference
35). The fourth open reading frame (ORF4) of KSHV encodes
a protein that inhibits complement activation, as shown by our
group and others (29, 39, 41). We named this protein KSHV
complement control protein, KCP. KCP is similar in structure
and function to a group of human complement inhibitors be-
longing to the family of regulators of complement activation
(RCA). Like these cellular proteins, KCP modulates comple-
ment activation by inhibiting the C3 convertases (29, 39), key
enzyme complexes that are formed subsequent to complement
activation and that determine progression of the complement
cascade. ORF4 is a lytic gene (17, 41), and the KCP protein it
encodes has been found on the surface of both infected cells
and viruses (40, 41). Thus, KCP is likely to help protect virions
and infected cells against complement eradication. Moreover,
KCP may be multifunctional; we recently showed that, like
other human and viral RCAs, it binds to heparin and heparan
sulfate (27, 40). On the surface of virions, KCP may therefore
aid in viral attachment to host cells, as previously described for
the envelope glycoproteins K8.1 and gB (1, 3, 9, 44). Concen-
trating KSHV on the surface of target cells via binding to
heparan sulfate could enhance binding to its other specific
receptors (2, 19, 34), a strategy described for other herpes
viruses (37).
Kapadia et al. (20) evaluated the in vivo pathogenetic sig-
nificance of the murine gammaherpesvirus 68 (HV68) RCA.
These authors identified a critical role for the HV68 RCA in
determining virulence, since mutant virus lacking this protein
was attenuated. Moreover, mutant virus lacking the HV68
RCA protein and wild-type HV68 were equally pathogenic in
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complement component C3-deficient mice, underscoring the
complement dependency of this attenuation. In contrast, these
authors found no effect of HV68 RCA in studies of latency.
Such studies of the contribution of KCP to KSHV infection
and pathogenesis in the natural host are obviously impossible.
However, murine models are being developed that may be
amenable to such KSHV work (6, 33, 46). Another putative
model for KSHV is the non-human primate gamma2-herpes-
virus, rhesus rhadinovirus (RRV). RRV replicates to high titer
in cell culture (15) and infects rhesus monkeys, providing an in
vivo model of KSHV-like infection since the gene organization
and genomic sequences share similarity (5, 7, 25, 36, 45). RRV
infection of rhesus macaques is therefore considered a useful
animal model to study the relevance of individual genes for
rhadinovirus biology in a primate host. Moreover, RRV can
yield lymphoid hyperplasia resembling Castleman’s disease
when combined with simian immunodeficiency virus-induced
immunosuppression (45) as well as transient lymphadenopathy
in simian immunodeficiency virus-negative macaques (25). The
genomes of two RRV isolates, called H26-95 and 17577,
have been sequenced to date (GenBank accession numbers
AF210726 and AF083501, respectively) (5, 36). Each strain
encodes a KCP homologue. This protein has been named
RRV complement control protein, RCP, by others (31), in
keeping with existing nomenclature for this type of viral com-
plement inhibitor (i.e., vaccinia virus complement control pro-
tein and KCP). Thus, as a prelude to investigating the function
of a primate gammaherpesvirus complement regulatory pro-
tein in vivo, we have performed primary characterization and
functional studies on RRV RCP and the protein(s) it encodes.
While most gene products from the two different RRV isolates
are predicted to share around 98% amino acid sequence sim-
ilarity (5), the predicted RCP proteins from the two strains are
quite different. They are referred to herein as RCP-H (RCP
encoded by strain H26-95) and RCP-1 (RCP of strain 17577).
RCP-H contains four complement control protein (CCP) do-
mains (TrEMBL accession number Q9J2M6), like the KSHV
KCP, while RCP-1 has eight CCP domains (TrEMBL acces-
sion number Q9WRU2). Both RCPs have a predicted C-ter-
minal transmembrane region.
Given the structural diversity of RCP-H and RCP-1, we
studied both genes and the proteins they encode. Rapid am-
plification of cDNA ends (RACE) PCR identified the 5 and 3
ends of the genes, and their expression in RRV-infected cells
was measured by reverse transcriptase PCR (RT-PCR) and
Western blotting. RCP-1 is expressed as a full-length mRNA
and two alternatively spliced transcripts, while RCP-H RNA is
not spliced. Recombinant RCP-H and RCP-1 expressed on the
surface of Chinese hamster ovary (CHO) cells inhibited com-
plement activation by the classical (antibody-mediated) path-
way, measured by their inhibition of C3b deposition on the cell
surface. Further data confirmed the presence of RCP on the
surface of RRV, like KSHV-encoded KCP.
MATERIALS AND METHODS
Virus and cell culture. Cell-free seed stocks of RRV 17577 and H26-95 were
grown initially in primary rhesus macaque (Macaca mulatta) fibroblasts (RFB).
Thereafter, RRV-infected cells were either primary RFB or RFB that were
transduced with a retrovirus expressing human telomerase and referred to as
transformed RFB (tRFB). Prior to their inoculation with virus, the cells were
treated with polybrene (hexadimethrine bromide; catalogue no. H9268; Sigma,
St. Louis, MO) at 2 g/ml for 60 min. RRV naturally undergoes lytic replication
in RFB and tRFB, with cytopathic effect (CPE) detectable by approximately 5
days postinfection. Cells were cultured in Dulbecco’s modified Eagle’s medium,
supplemented with 1% nonessential amino acids, 1% glutamine, and 10% de-
fined fetal bovine serum (catalogue no. SH30070; HyClone South Logan, UT).
CHO cells were purchased from ATCC and propagated in RPMI 1640 cell
medium (GIBCO) containing 10% fetal calf serum, 4 mM L-glutamine, 50 U/ml
penicillin, and 50 g/ml streptavidin.
Mapping of 5 and 3 ends of RCP transcripts. Primary rhesus fibroblasts were
infected with cell-free 17577 or H26-95 RRV. After development of CPE, 5 to 10
days postinfection, total cell RNA was isolated with TRIzol (GIBCO, Invitrogen,
Carlsbad, CA), according to the manufacturer’s protocol. Transcript 5 and 3
ends were mapped with a GeneRacer kit (Invitrogen), according to the manu-
facturer’s instructions. Briefly, 15 to 600 ng of total RNA was used per reaction.
An RNA oligonucleotide from the GeneRacer kit was ligated selectively to the
mRNAs with an intact 5 end, and reverse transcription was carried out with
oligo(dT) primers and the Superscript III RT. PCRs were then performed on the
resulting cDNA with one primer from the GeneRacer kit, annealing either to the
sequence originating from the RNA oligonucleotide ligated to the 5 end or to a
3 sequence originating from the oligo(dT) primer. Gene-specific primers were
designed to anneal around 200 to 250 bp either downstream of the putative
initiating ATG or upstream of the putative translation TAA stop codon: 5-
RCP-1, GCAAGTCAGCAGGTGTGGGACATCTT; 3-RCP-1, CGCCAACG
CCAGAAGCACCCAAACCAAA; 5-RCP-H, GCGTTTGGTGTAGTCCAC
GTTCCGTTT; and 3RCP-H, CAGACAACAACCAATCGGCCATCAA.
The sequences of all other primers in the present study are available on
request. Specific PCR products were TA cloned into the pCR4-TOPO vector
provided with the GeneRacer kit. A total of 10 to 30 colonies of each RACE
construct were sequenced. Nucleotide sequences were analyzed manually to
identify the consensus DNA sequences, TATA, AATAAA, and YGTGTTYY.
RT-PCR analyses of RCP transcripts. RNA was isolated from RRV-infected
rhesus fibroblasts at the emergence of CPE, as described for the RACE proce-
dure. Contaminating DNA was removed by treatment with DNase I (RQ1
DNase; Promega, Madison, WI) according to the manufacturer’s instructions.
The RT reaction was carried out using the oligo(dT) primer, Superscript III RT,
and transcriptase buffer from the GeneRacer kit (Invitrogen), according to the
manufacturer’s instructions, followed by RNase H treatment. RCP cDNA was
amplified by PCR with sequence-specific primers and Platinum Pfx DNA poly-
merase (Invitrogen), followed by incubation with Taq DNA polymerase to add 3
A-overhangs. The PCR products were cloned into either the pCR4-TOPO vector
(Invitrogen) or the pPCR-Script Amp SK() vector (Stratagene, La Jolla, CA)
and sequenced.
Cloning of genomic DNA encoding RCP. RRV H26-95 or 17577 particles were
lysed by heating to 95°C for 30 min. The crude lysate served as a PCR template
in a reaction employing Pfu polymerase (Fermentas, Vilnius, Lithuania). 3
A-overhangs were then added with Taq polymerase (Invitrogen), and the PCR
products were ligated into the pCR4-TOPO vector for sequencing (Invitrogen).
The inserts were sequenced and found to be identical to the corresponding parts
of the published RRV genomes (GenBank accession numbers AF083501 and
AF210726).
Production of polyclonal anti-RCP antibodies. Polyclonal anti-RCP antibodies
were produced by the method described previously for antibodies against KCP
(26). DNA fragments encoding CCP domains 1 to 2 (CCP1-2) and CCP5-6 from
RCP-1 and CCP1-2 from RCP-H were amplified by PCR. The primers intro-
duced sites for the restriction enzymes NdeI and XhoI to enable insertion of the
DNA fragments into the prokaryotic expression vector pET-38b() (Novagen,
EMD Biosciences, Madison, WI) in frame with a C-terminal cellulose binding
domain tag from an exoglucanase (CBDcex) and an N-terminal His tag. The
proteins were expressed by the Escherichia coli strain BL21-CodonPlus (DE3)-
RIPL and accumulated in inclusion bodies. The inclusion bodies were isolated
after lysis of the bacteria with lysozyme treatment (200 g/ml in phosphate-
buffered saline [PBS]) and sonication, washed in PBS, and then dissolved by
sonication in 6 M guanidine HCl, 10 mM reduced glutathione, and 20 mM
Tris-HCl (pH 8). Recombinant protein was purified by a nickel-nitrilotriacetic
acid Superflow column (QIAGEN, Venlo, The Netherlands). The protein was
refolded, when bound to the nickel matrix, by application of a linear gradient
starting with 6 M guanidine HCl, 10 mM reduced glutathione, and 20 mM
Tris-HCl (pH 8) and ending in 50 mM Tris-HCl, pH 8, followed by washing in 50
mM Tris-HCl, pH 8, plus 20 mM imidazole. The protein was then eluted with 0.7
M imidazole. Eluted protein was a mixture of monomeric RCP molecules and
aggregates, as determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and Coomassie brilliant blue staining (data not shown). To sep-
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arate these species, the protein was dialysed against 50 mM Tris, pH 8.5, and
then applied to a MonoQ column (GE Health Care, Fairfield, CT) equilibrated
in the same buffer. Proteins were eluted with a salt gradient ranging from 0 to 0.5
M NaCl in the equilibration buffer. Fractions containing unaggregated protein
were dialysed against PBS and used for immunization of rabbits according to a
standard protocol at Cardiff University. The resulting sera are referred to as
polyclonal antibodies (pAb) throughout the text.
Western blotting. Cell lysates were prepared from either RRV-infected tRFB
demonstrating significant CPE or from CHO cells stably transfected to express
recombinant forms of RCP. Cells were detached from the culture flask by an
EDTA-containing buffer to ensure cell surface protein integrity and then dis-
solved in a solubilization buffer (1% Triton X-100, 20 mM Tris-HCl, pH 8.0, 0.15
M NaCl, 5 mM EDTA, 1% Trasylol, and 2 mM phenylmethylsulfonyl fluoride
[PMSF]). SDS-polyacrylamide gel electrophoresis was performed with a 12%
acrylamide resolving gel. Denatured lysates were prepared by adding an equal
volume of 2 SDS loading buffer (100 mM Tris-HCl, pH 6.8, 4% [wt/vol] SDS,
20% [vol/vol] glycerol, 3% [vol/vol] 2-mercaptoethanol, 0.05% [wt/vol] bromo-
phenol blue) and heating to 100°C for 2 min. A total of 5 g of each lysate was
loaded, as determined by a Bradford assay. Cell culture fluid of RRV 17577-
infected tRFB was also analyzed by Western blotting, after being concentrated
threefold through a YM-10 Centriplus filter device (Millipore) by centrifugation
(3,200  g for 16 h at 4°C). Both the concentrate and flowthrough were analyzed.
Western blotting was performed according to the method of Towbin et al. (42).
Resolved proteins were transferred to a 0.45-m-pore-size Immobilon-P mem-
brane (Millipore, Billerica, MA) by electrophoresis. Proteins were detected with
primary antibody at a dilution of 1:250 and in turn detected by horseradish
peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) secondary
antibody (Dako, Glostrup, Denmark). The antibody-protein complex was visu-
alized by enhanced chemiluminescence. Equal volumes of solution 1 (2.5 mM
luminol, 0.4 mM p-coumaric acid, 100 mM Tris-HCl, pH 8.5) and solution 2
(0.0192% [vol/vol] H2O2, 100 mM Tris-HCl, pH 8.5) were mixed and added to
the membrane. After about 1 min, excess solution was blotted off, and the
membrane was exposed to autoradiographic film.
Chemical deglycosylation. Aliquots of tRFB cytosol containing 1 mg of total
protein were lyophilized overnight. Deglycosylation was performed on the
freeze-dried samples using a GlycoProfile IV chemical deglycosylation kit
(Sigma) as instructed by the manufacturer. The samples were then dialysed
against PBS using tubing with a molecular size cutoff of 12,000 kDa.
IEM. RRV for immune electron microscopy (IEM) was prepared from the
culture fluid of infected tRFB showing CPE. Cells and debris were removed by
centrifugation (1,900  g for 5 min at 4°C), and virions were then concentrated
(13,000  g for 180 min at 4°C) before being resuspended in serum-free medium
by overnight incubation at 4°C. The IEM procedure was performed essentially as
described for staining KSHV virion-associated KCP (40). Briefly, RRV was
applied to Parlodion-coated 200-mesh nickel grids (Agar Scientific, Stansted,
United Kingdom). RCP was detected by staining with polyclonal anti-RCP an-
tibody pAb H2612. The grids were washed in PBS, and bound antibody was
detected with goat anti-rabbit antibody conjugated to 5-nm gold (British Biocell,
Cardiff, United Kingdom). Preparations were negatively stained with phospho-
tungstic acid, pH 7 (Agar Scientific, United Kingdom), and viewed with a Jeol
1200 electron microscope (80kV; magnification, 40,000). As a negative control,
preimmune serum was used instead of pAb H2612.
Eukaryotic cell surface expression of RCP and C3b deposition assay. In order
to assess RCP regulation of complement activation, membrane-bound RCP was
expressed with a glycosylphosphatidylinositol (GPI) anchor from human decay-
accelerating factor (DAF; CD55) in the C-terminal part of the protein, as
described previously for KCP functional studies (41). To achieve this expression,
DNA encoding the soluble parts of RCP-1 and RCP-H, ending approximately 50
amino acids after the most C-terminal CCP domain, was amplified by PCR with
appropriate primers from the respective full-length RCP genes in pCR4-TOPO.
These fragments were cloned with the restriction enzymes XbaI and NotI into a
derivative of the pDR2EF1 vector (41) that contained the cDNA signal for GPI
anchor addition and transfected with Lipofectamine (Invitrogen) into CHO cells.
Following selection with hygromycin B (Roche, Basel, Switzerland), cell surface
RCP expression on stable transfectants was confirmed by flow cytometric anal-
yses with our polyclonal antibodies against RCP-H and RCP-1. For this analysis,
the cells were detached with Versene (Invitrogen) and incubated with serum
from the RCP-immunized animals [diluted 1:100 in binding buffer (10 mM
HEPES, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, pH 7)], for 1 h
at room temperature, followed by incubation for 45 min with fluorescein iso-
thiocyanate (FITC)-labeled anti-rabbit antibodies (catalogue no. F0205;
DAKO), diluted 1:75.
C3b deposition was quantified on the surface of the stable CHO transfectants,
expressing either RCP or KCP (39), or on mock-transfected cells. The cells were
detached with Versene and washed twice with binding buffer. Between 200,000
and 500,000 cells per sample were sensitized with anti-hamster lymphocyte serum
(catalogue no. H-4769; Sigma, Poole, United Kingdom), diluted 1:40, and in-
creasing concentrations of fresh-frozen normal human serum diluted in
DGVB (2.5 mM veronal buffer, pH 7.35, 72 mM NaCl, 140 mM glucose,
0.1% gelatin, 1 mM MgCl2, and 0.15 mM CaCl2).
C3b was quantified by washing the cells with binding buffer and then incubat-
ing them with rabbit anti-human C3c FITC-conjugated antibodies (catalogue no.
F0201, diluted 1:100 in binding buffer; DAKO) for 30 min at room temperature.
Fluorescence-activated cell sorting buffer (50 mM HEPES, 100 mM NaCl, 30
mM NaN3, 1% bovine serum albumin, pH 7.4) was added, and the cells were
then analyzed with a Becton Dickinson FACSort flow cytometer (BD Bio-
sciences, Franklin Lake, NJ). The mean fluorescence intensity (MFI) provided a
measurement of the extent of C3b deposition. The experiments were carried out
in triplicate, and data were acquired on 5,000 cells.
Detection of anti-RCP antibodies in rhesus serum. Serum was drawn from a
rhesus monkey experimentally infected with RRV 17577 and from a noninfected
control. Both animals were housed at the Oregon National Primate Research
Center, Beaverton, OR, and were cared for according to institutional guidelines.
Serum was also obtained from two RRV H26-95-infected monkeys, animals Mm
122-96 and Mm 193-96, from the New England Regional Primate Research
Center, Southborough, MA. Serum proteins were precipitated with (NH4)2SO4
at 60% of saturation and then dissolved in and dialysed against PBS. The
preparations from each animal were adjusted to contain equal amounts of pro-
tein, as determined by UV spectroscopy. Microtiter plates (Maxisorp; Nunc)
were coated with RCP-tagged CBDcex expressed in bacteria (described above) by
incubation with a 10 g/ml solution of the protein in 75 mM Na2CO3, pH 9.6, at
4°C overnight. The wells were blocked by incubation with quench buffer (3% fish
gelatin, 10 mM Tris HCl, 75 mM NaCl, 0.05% Tween 20, pH 8.0) for 1 h at room
temperature. The plates were then incubated with the rhesus serum proteins,
diluted in quench buffer for 90 min at room temperature, followed by incubation
with rabbit anti-human serum that cross-reacts with rhesus Ig (our data not
shown, data found in reference 32, and data from the manufacturer). These sera
were anti-human IgG (catalogue no. A0423; DAKO) and anti-human IgM
(catalogue no. A0425; DAKO), diluted 1:1,000 in quench buffer for 1 h at room
temperature. An HRP-conjugated anti-rabbit antibody (catalogue no. P0448;
DAKO), diluted 1:1,000 in quench buffer, was then added for 1 h at room
temperature. Between each incubation step, the microtiter plates were washed
with 10 mM Tris HCl, 75 mM NaCl, 0.05% Tween 20, pH 8.0. Bound antibodies
were detected using OPD (o-phenylenediamine dihydrochloride) tablets
(DAKO) dissolved in H2O and supplemented with H2O2.
RESULTS
Mapping the 5 and 3 ends of the RCP transcripts. To
identify the 5 and 3 ends of the RCP genes, the RACE
procedure was performed on RNA prepared from RRV-in-
fected primary RFB demonstrating CPE. Between 10 and 30
cDNA PCR clones derived from each transcript were se-
quenced, and the results are presented in Fig. 1. For RCP-H,
the mRNA start site was unambiguously mapped to the posi-
tion 10 nucleotides upstream of the predicted ATG start
codon. The most preferred initiation start site for RCP-1 was
25 nucleotides upstream of the ATG start codon (25; eight
clones), but the transcription initiation was less stringently
controlled than for RCP-H, since a further six clones identified
an initiation site at position 22. Another six clones revealed
putative transcription start sites to be scattered about this
region of the gene. However, since no more than one clone
identified each site, the sites specified by these six clones are
deduced to be of minor relevance and may be artifacts arising
due to RNA degradation during sample treatment.
Examination of the sequences about the identified 5 and 3
ends of the genes revealed conserved motifs for the promoter
(TATA) (11) and for polyadenylation (AATAAA and YGTG
TTYY) (28, 43).
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Primary sequence analysis of RCP proteins and comparison
with KCP. To identify similarities and differences between
RCP from the two strains and KCP, their amino acid se-
quences were compared. CCP domains are predicted for all
three proteins by sequence analysis tools (41; also SMART at
http://smart.embl.de/). A CCP domain consists of approxi-
mately 60 amino acid residues that are arranged into antipar-
allel -sheets, forming a -sandwich arrangement stabilized by
four cysteine residues that form two disulfide bonds in a
1–3,2-4 pattern, and conserved hydrophobic and aromatic res-
idues that form a hydrophobic core (30).
These sequence analyses predict that RCP-1 contains eight
CCP domains, whereas RCP-H has four, like KCP (Fig. 2). All
three proteins have a transmembrane domain in the C termi-
nus. KCP exists in three isoforms due to splicing of its mRNA,
where both shorter forms retain the transmembrane region as
well as the four CCP domains (41). In between the last CCP
domain and the transmembrane region, all three proteins have
a region that is predicted to contain several O-glycosylated
serine and threonine residues. This type of sequence is present
also in the region between CCP4-5 in RCP-1.
Pairwise alignment of the amino acid sequences in the CCP
domains was performed by BLAST analyses (for which RCP-1
was divided into CCP1-4 and CCP5-8) (Table 1). The blocks of
four CCP domains ranged in similarity from 58 to 63% (41 to
47% identity), with the exception of RCP-H CCP1-4 aligned
with RCP-1 CCP5-8, which had much higher similarity (80%
similarity and 64% identity).
Multiple splice forms of RCP-1 mRNA and a single RCP-H
mRNA. To determine whether the RCP transcript of either
RRV strain is alternatively spliced, like KSHV KCP (41), RT-
PCR analyses of primary RFB infected with RRV were per-
formed. PCR primers were designed to anneal downstream of
the transcription start and upstream of the transcription stop
sites, determined from our RACE transcript mapping. A sin-
gle, unspliced mRNA was detected for RCP-H. However, three
different RCP-1 mRNA species were identified (Fig. 3, left).
The largest mRNA was not spliced and encodes the predicted
RCP-1. The two shorter mRNAs arise due to splicing events.
There is one donor site and two acceptor sites (Fig. 3, middle);
FIG. 1. The 5 and 3 ends of the RCP genes. Parts of the genomes of RRV 17577 (GenBank accession no. AF083501) and RRV H26-95
(AF210726) at the 5 and 3 ends of the RCP genes are displayed. The predicted RCP start (ATG) and stop (TAA) codons are in boldface and
underlined. The detected mRNA start sites, as found by 5 RACE in the present study, are in boldface, and the number above the nucleotide
indicates the number of sequenced clones in which each site was found. For orientation, the number in parentheses indicates the position upstream
() of the ATG start codon or downstream () of the TAA stop codon. The mRNA stop site and location of the poly(A) tail were determined
by 3 RACE. The position in the genome is indicated at the beginning of each sequence. Putative TATA boxes are enclosed by a rectangle, the
consensus AATAAA box is underlined with two lines, and putative YGTGTTYY boxes are enclosed in rectangles with dashed lines, where Y
stands for pyrimidine. The lack of a G residue in the RCP-H YGTGTTYY box compared to that of RCP-1 is indicated with a minus sign.
FIG. 2. Analysis and comparison of predicted structures of RCP
and KCP. All three proteins have a signal peptide (sp) in the N
terminus. The ovals symbolize CCP domains. S/T boxes are areas with
predicted O-glycosylated serine and threonine residues, where the
number of O-glycosylation sites is indicated above the boxes. In the C
terminus there is a transmembrane region followed by a single intra-
cellular amino acid. Three isoforms of KCP have been identified due
to splicing events, for which the two donor and the single acceptor sites
have been identified (41).
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all obey the consensus G(U/A)G rule. The second largest
mRNA encodes a predicted protein in which the first CCP
domain is truncated (Fig. 3, right): the splice event causes loss
of the last 10 amino acids of CCP1, including the last cysteine
residue. CCP2-4 are also predicted to be absent, while CCP5-8
and the C-terminal region are present and in frame. The pre-
dicted size of this gene product is 40 kDa. The smallest mRNA
encodes a protein with the truncated first CCP domain and a
C-terminal end of 17 amino acids. Its molecular size is pre-
dicted to be 8 kDa. The splice acceptor site is downstream of
the RCP stop codon, and the C-terminal domain is frame-
shifted compared to the N-terminal part. No evidence of a
transmembrane domain in the C terminus of this putative
protein was found by sequence analysis using the TMpred tool
at EMBnet (http://www.ch.embnet.org).
Expressed RCP proteins. To determine if the identified
transcription profiles of RCP-1 and RCP-H mRNA coincided
with the expression profiles of the cognate proteins, Western
blot analyses of RRV-infected tRFB were performed. In ad-
dition, these analyses were performed on CHO cells engi-
neered to express recombinant RCP (rRCP) in which the pro-
tein was bound to the cell membrane via a GPI anchor derived
from human DAF and inserted in frame approximately 50
amino acids downstream of the most C-terminal CCP domain.
Polyclonal antibody pAb-1712, raised against recombinant
CCP1-2 of RCP-1, bound to proteins of an approximate size of
90, 66, and 40 kDa in cell lysates of 17577-infected RFB cells
(Fig. 4A). This antibody also detected 90- and 66-kDa proteins
from lysates of CHO cells expressing GPI-anchored recombi-
nant forms of rRCP-1 (Fig. 4C). The 90-kDa and 66-kDa
bands are inferred to be glycosylated forms of the proteins
encoded by the full-length and middle size mRNAs of RCP-1,
respectively, which encode proteins with masses of 69 and 40
kDa before posttranslational modification (see Discussion).
Indeed, chemical deglycosylation resulted in RCP isoforms
with a lower apparent molecular size (Fig. 4F and G), confirm-
ing that the expressed RCP-1 isoforms are glycosylated; the
slight discrepancy in the apparent molecular sizes of the pro-
tein bands in Fig. 4F, G, and H compared with the sizes in Fig.
4A to E is due to differences in the molecular size markers
used in the deglycosylation study. Antibody pAb-1712 also
detected only the 90-kDa species in virion-rich, cell-free su-
pernatant, even after longer exposures of the photographic
FIG. 3. Splicing pattern of RCP mRNA. RNA was extracted from rhesus fibroblasts that were infected with RRV. Reverse transcription
generated cDNA, which was amplified with RCP-specific primers. The positions of the primers are indicated in the middle panel, as lines called
fwd and rev. The resulting PCR products are shown in the left panel. The presence () or absence () of RT during the cDNA reaction is indicated
above the lanes. One PCR product was obtained for RCP-H and three for RCP-1. These products were subcloned and sequenced. The cartoon
in the middle panel interprets the sequence data (not to scale), with the transcript ends identified by RACE (Fig. 1). The PCR product from RCP-H
represents the entire predicted ORF. For RCP-1, the largest PCR product represents the full-length gene. The nucleotides of certain key features,
such as the protein start (ATG) and stop (TAA) codons, are given with their positions in the viral genome. The gray shading indicates a frameshift
with respect to the full-length protein. The panel to the right describes the predicted proteins that are encoded by the different splice variants. Ovals
represent CCP domains, vertical double lines are the transmembrane regions, and the bold line in gray indicates the frameshift. Amino acids and
their positions in the full-length protein are shown at the splice border.
TABLE 1. A comparison of the identity and similarity of CCP




RCP-H CCP1-4 RCP-1 CCP5-8 64 80
RCP-H CCP1-4 RCP-1 CCP1-4 47 63
RCP-1 CCP1-4 RCP-1 CCP5-8 45 64
RCP-1 CCP1-4 KCP CCP1-4 45 63
RCP-1 CCP5-8 KCP CCP1-4 45 58
RCP-H CCP1-4 KCP CCP1-4 41 58
a The following amino acid residues were used (numbering refers to full-length
proteins containing their signal peptide): 27 to 270 for RCP-H CCP1-4
(Q9J2M6); 23 to 265 for RCP-1 CCP1-4 (Q9WRU2); 320 to 562 for RCP-1
CCP5-8 (Q9WRU2); and 25 to 266 for KCP CCP1-4 (P88903). The TrEMBL
accession numbers are in parentheses. Alignment was performed at http:
//www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi, using the BLOSUM62 matrix
algorithm.
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film during Western blot analyses (Fig. 4A). The 66-kDa pro-
tein was detected at lower efficiency than the 90-kDa protein
under all conditions by pAb-1712 (Fig. 4A and C), including in
the virion-rich supernatant (Fig. 4A). This reduced detection
could be due either to the predicted loss of cognate epitopes
within CCP2 and 10 amino acid residues of CCP1 missing in
this isoform, since pAb-1712 only recognizes CCP1-2 or to
lower expression of the 66-kDa protein. The identification of
the RCP-1 40-kDa protein is ongoing and no RCP-1 8-kDa
protein was detected (see Discussion).
Staining RRV 17577-infected cell lysates with polyclonal
antibody pAb-1756 (Fig. 4B), raised against CCP5-6 of RCP-1,
identified the two bands that correspond in size and staining
intensity to the 90- and 66-kDa bands of Fig. 4A. There is also
a band slightly smaller than the 90-kDa species, of approxi-
mately 75 kDa. This protein is likely a more glycosylated vari-
ant of the 66-kDa protein, since it does not appear in the
deglycosylated sample (Fig. 4G). Three minor bands in the size
range 40 to 60 kDa are also detected with pAb-1756 in RRV
17577-infected cells upon long exposure (Fig. 4B); the middle-
sized protein (ca. 55 kDa) is also detected in mock-infected
cells, indicating some cross-reactivity of this antibody with one
or more cellular proteins. Antibody pAb-1756 also detected
the equivalent 90- and 66-kDa recombinant forms in trans-
fected CHO cells expressing rRCP-1 (Fig. 4D). Since very
weak reactivity with a 70-kDa band was observed for H26-95-
infected RFB (Fig, 4B) and slightly stronger reactivity to this
protein was detected in transfected CHO cells expressing
rRCP-H (Fig. 4D), pAb1756 is most likely cross-reacting with
the RCP-H protein that is the most similar in sequence to
RCP-1 (Table 1). Antibody pAb-1756 also cross-reacted with
the cellular protein of 55 kDa in untransfected CHO controls
(Fig. 4D), detected in mock-infected cells (Fig. 4B), as well
as demonstrating mild reactivity with other bands (Fig. 4B
and D).
Polyclonal antibody pAb-H2612, raised against CCP1-2 of
RCP-H, bound a protein of approximately 70 kDa in lysates
from H26-95-infected RFB cells (Fig. 4E), the presumptive
glycosylated variant of the full-length protein encoded by
RCP-H, as confirmed by chemical deglycosylation studies (Fig.
FIG. 4. Native RCP expression in RRV-infected rhesus macaque
fibroblasts and rRCP expression in engineered CHO cells. Cell lysates
(5 g of total protein) of either RRV-infected tRFB or CHO cells
transfected with plasmid expressing rRCP were loaded in each lane.
Exceptions are the supernatant loaded in panel A and samples with 8
g of total protein in panels C and D. The uppermost text indicates
which form of RCP was detected and from which cell-type. “Mock”
refers to either noninfected rhesus fibroblasts or CHO cells transfected
with an empty expression vector. Membranes were probed with anti-
bodies indicated above the blots. These antibodies were directed to
either RCP-1 CCP1-2 (pAb 1712) or RCP-1 CCP5-6 (pAb 1756) or
RCP-H CCP1-2 (pAb H2612). Next, the membranes were incubated
with anti-goat anti-rabbit HRP-conjugated antibody. Bound antibody
was detected by chemiluminescence, and a number of different lengths
of film exposure were processed. Equal loading of lysates was verified
by measuring -actin levels (lower panels). The dashed line in panel A
indicates the boundary between two separate blots. Panels A to E
present results of unmodified, denatured proteins. In panels F to H,
chemically deglycosylated RCP (deg) from RRV-infected tRFBs was
compared to unmodified RCP from the same cells.
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4H). Antibody pAb-H2612 also detected the GPI-anchored
rRCP-H in transfected CHO cells (Fig. 4E). The GPI-an-
chored rRCP-H is slightly smaller than the virion-expressed
RCP-H due to a reduced number of amino acid residues.
Unlike studies with pAb-1756, no cross-reactivity with the
other RCP (RCP-1) was noted for pAb-H2612 (Fig. 4E).
RCP detection on RRV virions. We have shown previously
that KCP is located on the virion envelope and the surface of
complete virions (40). Therefore, we reasoned that RCP would
be expressed on the surface of RRV, and this supposition was
confirmed by IEM. Figure 5A and B show RCP-H expression
on the surface of H26-95 virions detected with pAb-H2612 and
gold-conjugated secondary antibodies but not with preimmune
rabbit serum (Fig. 5C and D).
RCP antibodies in rhesus macaque monkeys infected with
RRV. The presence of anti-RCP antibodies in the serum was
determined with a modified enzyme-linked immunosorbent
assay in which the assay wells were coated with recombinant
proteins containing two CCP domains of either RCP-1 or
RCP-H. Serum was drawn from one rhesus monkey exper-
imentally infected with the 17577 strain of RRV and two
infected with RRV H26-95 (animals Mm 122-96 and Mm
193-96). The serum from the RRV-infected monkeys con-
tained substantial antibody titers against the respective vari-
ants of RCP (Fig. 6). Very low levels of RCP antibodies
were detected in the noninfected control monkey and were
of the IgM isotype (data not shown). Some cross-reactivity
was demonstrated by antibodies from the RRV 17577-in-
fected monkey to RCP-H.
RCP at the surface of CHO cells protects against comple-
ment-mediated lysis. The capacity of RCP to regulate comple-
ment activation was determined according to the method by
which we first showed KCP to inhibit complement activation
(41). The CHO cells engineered to express recombinant GPI-
anchored rRCP-1 or rRCP-H contained similar isoforms as
RRV-infected rRFB cells (Fig. 4C to E) and were examined by
flow cytometry with the polyclonal antibodies to ensure cell
surface expression (Fig. 7A). CHO cells expressing KCP were
also included as a positive control. The cells were sensitized
with anti-CHO antibodies to activate the classical complement
cascade and thereafter incubated with increasing concentra-
tions of human serum. Resultant C3b deposition mediated by
classical complement pathway activation was quantified by flow
cytometry, staining with an anti-C3b antibody directly conju-
gated to FITC. Recombinant RCP from both RRV strains
protected the cells against human C3b deposition in a manner
comparable to KCP (39).
DISCUSSION
KSHV encodes the complement inhibitor KCP. The effect of
KCP on the complement system has been well characterized in
FIG. 5. RCP is present on the surface of RRV virions. (A and B) RRV H26-95 particles were purified and stained with pAb H2612 that was
detected with gold-conjugated secondary antibodies, visible as black dots. Panel B shows an enlargement of the field of view shown in panel A.
(C and D) As a negative control, RRV H26-95 particles were stained with preimmune serum instead of pAb H2612. Panel D is an enlargement
of the field of view shown in panel C.
FIG. 6. Sera from RRV-infected rhesus monkeys contain antibod-
ies against RCP. (A to C) Serum from a 17577-positive monkey was
compared to that of a noninfected monkey. Microtiter plates were
coated with CCP1-2 (A) or CCP5-6 (B) from RCP-1 or CCP1-2 from
RCP-H (C) expressed in E. coli. Different dilutions of serum from the
17577-positive or noninfected monkey were added to the wells, and
bound antibodies were captured by a mixture of goat anti-human IgG
and IgM antibodies. (D) Microtiter plates were coated with CCP1-2
from RCP-H. Different dilutions of serum from either of two RRV
H26-95-infected monkeys or a noninfected monkey were added, and
bound antibodies were detected as described for panels A to C.
ELISA, enzyme-linked immunosorbent assay.
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vitro, but the study of the biological impact of KCP for KSHV
is confounded by the difficulty of culturing the virus in cell
culture and the lack of an animal host. New small-animal
model systems may help to alleviate this deficiency (6, 33, 46),
although they are not primate based. RRV infection of rhesus
macaques provides the most promising animal model in this
regard to study pathophysiology and therapeutic interventions
in the primate setting.
Thus, to ascertain the function and evaluate the mechanism
of action of the RRV complement regulatory protein, we have
performed primary characterization of the RCP genes of the
two sequenced strains H26-95 and 17577. These data enabled
cloning of the genes from both strains and, thereby, the ex-
pression of the proteins for functional studies and the gener-
ation of antibodies.
The sites of RCP transcription initiation and termination
were mapped (Fig. 1). Transcription initiation occurred either
25 nucleotides (RCP-1) or 10 nucleotides (RCP-H) upstream
of the putative translation initiation codons, increasing their
credibility. Putative TATA boxes were found 33 (RCP-1) and
30 (RCP-H) bp upstream of the identified transcription initia-
tion start sites, consistent with their normal situation for mam-
malian genes (11). An additional candidate TATA box posi-
tioned 69 bp upstream of RCP-1 is less ideally situated.
Although the TATA boxes follow the consensus rules (11),
they are not identical for RCP-1 and RCP-H, and neither of
them is identical to the TATA box identified upstream from
KCP (41). Both RCP genes have a Kozak element containing
the important residue A three nucleotides upstream of the first
methionine codon, but they lack G at position 4, suggesting
that the context of these methionine codons is reasonably
favorable (22, 23).
The 3 ends of the RCP genes are identical. The polyade-
nylation site is 127 bp downstream of the stop codon. This site
is preceded by the consensus AATAAA signal, present in most
transcripts transcribed by RNA polymerase II (43). Approxi-
mately 30 bp downstream of the AATAAA box is a sequence
adhering well to the YGTGTTYY consensus sequence found
in certain herpesvirus genes and two-thirds of surveyed mam-
malian genes and thought to be involved in efficient 3 RNA
processing (28). Taken together, this analysis indicates that
RCP-1 and RCP-H maintain a conventional eukaryotic gene
organization.
Splicing of KSHV genes is well documented (for review, see
reference 47), and the KSHV ORF4, or KCP, encoding KCP is
expressed as a full-length transcript along with two alterna-
tively spliced mRNAs; all three mRNA species specify mem-
brane-bound KCP isoforms (41). Therefore, after the 5 and 3
ends of the RCP genes were mapped, the transcripts of RRV-
infected cells were analyzed by RT-PCR for alternative splic-
ing. Three splice variants of the RCP-1 mRNA from strain
17577 were identified (Fig. 3). The largest, unspliced RCP-1
transcript encodes the full-length RCP-1 protein, with eight
CCP domains and a transmembrane region. The two smaller
mRNAs arise through alternative splicing, where the splice
donor sites are conserved and the acceptor sites differ. Each
spliced transcript species specifies an RCP-1 isoform that is
truncated in CCP1, resulting in the deletion of the carboxyl
terminal 10 amino acid residues, including the fourth cysteine.
This cysteine residue forms one of the two disulfide bonds that
contribute to the tertiary structure of a CCP domain. It is
therefore not clear what kind of conformation this truncated
CCP domain adopts. Nevertheless, the full-length and middle-
sized mRNAs of RCP-1 are expressed; proteins with the ap-
proximate apparent sizes of 90 and 66 kDa are detected with
pAb-1712 and pAb-1756 (directed against CCP1-2 and CCP5-6
of RCP-1, respectively) in Western blot analyses of cell lysates
of both RRV 17577-infected RFB as well as CHO cells ex-
pressing recombinant RCP-1 (Fig. 4). The predicted masses of
the proteins encoded by the full-length and middle-sized splice
forms are 69 and 40 kDa, respectively. The increased apparent
molecular mass is likely due to glycosylation on any of the
predicted N- and O-glycosylation sites found within the pro-
tein (http://www.cbs.dtu.dk/services/NetNGlyc/and http://www
.cbs.dtu.dk/services/NetOGlyc/, respectively) (18). Chemical
FIG. 7. rRCP-H and rRCP-1 inhibit C3b deposition. CHO cells
were transfected with constructs encoding either recombinant mem-
brane-bound rRCP or rKCP. Negative control cells were transfected
with an empty vector. (A) The levels of rRCP and rKCP expression by
the transfected cells were determined by staining with polyclonal an-
tibodies directed against CCP1-2 of RCP-H, CCP1-2 or CCP5-6 of
RCP-1, and CCP1-2 of KCP. For rRCP expression, the negative con-
trols were stained in the same manner as the rRCP-transfected cells, as
indicated. For rKCP, the negative control is rKCP-expressing cells
stained with only the secondary antibody. (B) C3b deposition was
measured by flow cytometry. Cells were incubated with anti-hamster
antibodies and different concentrations of human serum to activate
complement and deposit C3b on the cell surface. The cells were then
stained with an anti-C3b antibody. The experiment was performed
twice in triplicate (or duplicate for rRCP-H). The geometric MFI
obtained for the vector-only control cells in 10% serum was set as
100% C3b deposition. The C3b deposition percentages were calcu-
lated for all of the individual samples. The average and standard
deviations of these values are plotted. A 100% C3b deposition corre-
sponded to a geometric MFI of 195 or 125.
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deglycosylation did, indeed, decrease the apparent molecular
size of the RCP isoforms (Fig. 4F-H).
The smallest RCP-1 isoform may also be expressed, since we
consistently detected by Western blotting a protein of ca. 40
kDa in RRV 17577-infected cell lysates (Fig. 4A) but not in
RRV H26-95-infected or noninfected cells. This protein was
not detected with pAb-1756, indicating that it lacks epitopes in
CCP5-6, consistent with its being translated from the smallest
mRNA variant. However, the predicted size of the protein
encoded by this smallest isoform is ca. 8 kDa, and it does not
contain any putative N- or O-glycosylation sites that could
explain a size of 40 kDa. We have not detected an 8-kDa
protein from RRV 17577-infected cells. Explanations include
the possibility that the 40-kDa protein could be a very stable
multimer of the smallest isoform, although the proteins were
separated under reducing conditions. Alternatively, it could be
the 8-kDa protein with covalently attached ubiquitin groups,
targeting it for intracellular degradation due to misfolding
(16). This possibility agrees with the absence of this protein in
the supernatant of RRV 17577-infected cells (Fig. 4A); it is not
secreted, despite having features of a secreted protein, includ-
ing a signal peptide but no additional transmembrane domain.
The 40-kDa protein was not present in lysates of CHO cells
expressing recombinant RCP-1 (Fig. 4C and D). In this con-
struct, the C-terminal transmembrane segment was replaced by
a GPI anchor link from human DAF. Therefore, the most 5
acceptor site in the RCP-1 mRNA is missing. The 40-kDa
protein could also be derived from an as yet unidentified
spliced isoform of RCP-1, and we cannot exclude the possibility
that it and, indeed, the other small RCP-1 isoform are gener-
ated by proteolytic processing. Nevertheless, studies to deter-
mine the identity of the 40-kDa protein are in progress.
Another example of a viral RCA with a partial CCP domain,
like the RCP-1 isoforms derived from spliced transcripts, is
MOPICE (monkeypox inhibitor of complement enzymes) en-
coded by the monkeypox virus (24), of which only the first
cysteine residue of the fourth CCP domain is present. The
reason for the existence of alternative RCP-1 isoforms is un-
clear, as it is for KCP. Herpesvirus saimiri encodes a comple-
ment regulatory protein, expressed as a membrane-bound pro-
tein from full-length mRNA and a soluble form from spliced
transcripts (4), but neither the KCP isoforms nor the two
largest RCP-1 isoforms are expected to be soluble; they are all
predicted to contain a transmembrane domain. Western blot
analysis of concentrated supernatant from RRV 17577-in-
fected cultures revealed low levels of the largest RCP-1 iso-
form, containing a membrane-spanning domain (Fig. 4A). The
manner by which this protein is released into the supernatant
is not known; possibly, it is cleaved from the cell surface, as was
proposed for the HV68 RCA (21). Alternatively, its presence
in the supernatant is due to its virion-association. The other
isoforms may also be present in the supernatant associated
with virions but at levels too low to detect by our assay.
RCP-H contains four CCP domains, similar to previously
described viral RCAs, while RCP-1 has eight CCP. The pair-
wise alignment performed for the CCP encoding sequences,
with RCP-1 divided into CCP1-4 and CCP5-8, revealed the
highest similarity between RCP-1 CCP5-8 and RCP-H (Table
1). If the eight CCP domains had arisen through a recent gene
duplication of a four-CCP precursor, as the presence of a short
S/T region between CCP4 and CCP5 suggests, a greater degree
of similarity between CCP1-4 and CCP5-8 would be expected.
However, although unlikely, a recombination event between
viral strains might explain the higher similarity between
CCP5-8 of RCP-1 and CCP1-4 of RCP-H. S/T-rich regions,
predicted to be heavily O-glycosylated, are commonly found
between the last CCP domain and the membrane, regardless of
whether attachment to the membrane is via a glycolipid anchor
or a transmembrane region and proposed to project the func-
tional CCP domains to a suitable location above the plasma
membrane (14). The presence of an S/T region between CCP
domains, as identified in RCP-1, is unique compared to all
other complement regulators identified (host and virus), and
its significance is under investigation.
IEM analyses indicated that RCP-H encoded by RRV
H26-95 is incorporated into the virion envelope. These data
are consistent with the primary structure of RCP-H, which
contains a membrane-spanning domain, and with our observa-
tions of KCP on the surface of KSHV virions (40). Moreover,
our data are consistent with the studies of O’Connor et al. (31),
who analyzed the protein composition of the different com-
partments of RRV H26-95 virions by mass spectometry and
found RCP-H in the lipid envelope at a level indicating that
RCP is more abundant than glycoprotein gL and as abundant
as gN. Taken together, several lines of evidence support the
presence of RCP-H on the virion surface, where it likely de-
fends the virus against complement-mediated lysis by the mem-
brane attack complex, the product of the terminal components
of the complement cascade. Whether RCP-H contributes to
cell binding, as KCP does for KSHV (40), is currently under
investigation.
That RCP modulates complement activation was demon-
strated by expressing the protein at the surface of CHO cells
on the DAF GPI anchor. Here, both RCP-1 and RCP-H re-
duced deposition of C3b on the cell surface, following comple-
ment activation by the classical pathway (Fig. 7). These data
indicate that RCP inhibits the classical C3 convertase, as does
KCP. KCP exerts this inhibition both by acting as a cofactor for
the serine protease factor I, enabling it to cleave C4b and C3b,
and by directly accelerating the decay of the classical C3 con-
vertase (29, 41). However, the mechanism(s) by which RCP
regulates the classical C3 convertase activity remains to be
determined. The C3b deposition assay was performed with
human serum, suggesting that RCP cross-reacts with human
complement components.
RRV-infected monkeys develop antibodies against RRV
proteins, with seroconversion detectable within a few weeks
after infection (25). Here, we show that antibodies can be
generated in vivo against RCP (Fig. 6), indicating that RCP is
expressed during the course of infection. Antibodies from
RRV-infected animals neutralize infectivity in a complement-
independent manner (8). Whether antibodies against RCP
contribute to this neutralization is currently being determined.
They may do so, for example, by either confounding a putative
role for RCP in mediating virus-cell attachment or interfering
with RCP complement regulation.
In conclusion, the present study adds another virus, RRV, to
the growing list of those known to modulate complement ac-
tivity (10). It serves to underline, therefore, the importance of
complement to the biology of viruses of diverse phylogeny and
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emphasizes the role that the study of viruses plays in elucidat-
ing the function and significance of the immune response.
These data also provide the framework for further studies on
the nature of the molecular interactions between RCP and the
complement system in vitro and in vivo in the non-human
primate.
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